QIAGEN announces expansion of Supervisory Board
20 Abril 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
that Steve Rusckowski, an internationally recognized healthcare
industry executive and former Chairman, President and CEO of Quest
Diagnostics, has joined the Supervisory Board as a new member and
will stand for election at the next Annual General Meeting
scheduled for June 22, 2023.
“It is with great pleasure that we welcome Steve
Rusckowski to our Supervisory Board. He has had a remarkable career
in the healthcare industry and a proven track record as the leader
of one of the world’s most important diagnostics companies. We are
looking forward to him making many contributions to the future
success of QIAGEN,” said Lawrence Rosen, Chair of the Supervisory
Board. “We are also looking forward to again meeting with our
shareholders in person at the Annual General Meeting in June. It is
an opportunity to show how QIAGEN is navigating a volatile macro
environment in 2023 and executing on a strategy that positions us
well for the future.”
Mr. Rusckowski most recently served as Chairman,
President and Chief Executive Officer of Quest Diagnostics
Incorporated. He joined Quest Diagnostics as President and Chief
Executive Officer in May 2012, and was named Chairman in 2016. He
stepped down from his role as President and CEO in 2022, and as
Chairman in early 2023. Prior to joining Quest Diagnostics, Mr.
Rusckowski was CEO of Philips Healthcare, which became the largest
unit of Royal Philips Electronics under his leadership. He joined
Philips in 2001 when it acquired the Healthcare Solutions Group he
was leading at Hewlett-Packard/Agilent Technologies. Mr. Rusckowski
previously served as a member of the Board of Directors of Xerox
Holdings Corporation and Covidien plc. He earned a bachelor’s
degree in Mechanical Engineering from Worcester Polytechnic
Institute and a master’s in Management from the Massachusetts
Institute of Technology’s Sloan School of Management.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare), Applied Testing (primarily
forensics), Pharma (pharma and biotech companies) and Academia
(life sciences research). As of December 31, 2022, QIAGEN
employed approximately 6,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, collaborations
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission
(SEC).
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Eltrop
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024